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Background: The purpose of this study is to evaluate the rate of perioperative bleeding complications
following anticoagulation therapy in patients undergoing implantable electronic device implantation.
Methods and results: We retrospectively analyzed the data from 161 consecutive patients with new
device implants or generator replacement performed between February 2008 and June 2009 in our
hospital. Sixty-ﬁve (40.3%) patients took warfarin, 55 (34.2%) took antiplatelet therapy, and 16 (9.9%)
took dual antiplatelet therapy prior to implantation. Heparin bridging was performed in 7 of 65 patients
taking warfarin. Pocket hematoma was observed in 10 (6.2%) patients and device infection was observed in
1 (0.6%) patient. No cases of thromboembolism were observed. There were no complications associated
with warfarin (P¼0.19) or antiplatelet therapy (P¼0.69). However, the patients that had undergone
heparin bridging were signiﬁcantly more likely to have complications (3 of 10) (P¼0.005). In multivariate
analysis, heparin bridging was the only independent predictor of complications.
Conclusion: Our study suggests that heparin bridging increases the risk of perioperative bleeding
complications in cardiac device implantation.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Recent trials of the use of implantable electronic devices,
including implantable cardioverter deﬁbrillators (ICDs) and cardiac
resynchronization therapy deﬁbrillators (CRT-Ds) show survival
beneﬁts [1–3]. As a result, implantable electronic devices are being
used with increasing frequency and the population of candidates
for implantable electronic devices has expanded to include patients
with additional comorbidities, such as atrial ﬁbrillation, poor left
ventricular systolic function, or the presence of mechanical cardiac
valves. These patients are generally orally anticoagulated to reduce
the risk of thromboembolism. Discontinuation of anticoagulation
therapymay increase risk of thromboembolism [4–6], and therefore
current guidelines recommend the cessation of oral anticoagulation
in favor of heparin bridging during the perioperative period [7–10].
In some studies, it has been shown that heparinization is associated
with an increased risk of hematoma development, while oral
anticoagulation therapy with warfarin did not increase the rate of
pocket hematoma [5,11–15]. There have been no reports on thert Rhythm Society. Published by E
: þ81 78 382 5859.
Fujiwara).relationship between anticoagulation and bleeding complications
after device implantation in Japan.
The purpose of this study was to evaluate the rate of the
perioperative bleeding complications following anticoagulation
therapy in patients undergoing electronic device implantation. We
have also attempted to identify the risk factors for complications.2. Methods
We retrospectively analyzed the data from 161 consecutive
device implants, including 112 new implants and 49 replacements,
performed between February 2008 and June 2009 in our hospital.
Implantable electronic devices include bradycardia pacemakers
(PMs), ICDs, and cardiac resynchronization therapy devices with
pacing only (CRT-Ps) or deﬁbrillation capability (CRT-Ds). No patients
were excluded from the analysis.3. Device implantation
Initially, a small amount of radiographic contrast material was
injected to deﬁne the subclavian anatomy in all patients except
for those with severe renal dysfunction. Ventricular leadlsevier B.V. All rights reserved.
Table 2
Indications for oral anticoagulation.
Number (%)
Atrial ﬁbrillation or ﬂutter 47 (72%)
Low EF 16 (25%)
Mechanical valve 7 (10%)










Blood transfusion 4 (2.5%)
Evacuation for hematoma 1 (0.6%)
Device extraction and reimplantation 1 (0.6%)
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and atrial lead placement was obtained by percutaneous sub-
clavian vein puncture. The lead placements were performed
under ﬂuoroscopic guidance. In most cases, the device was placed
subcutaneously under local anesthesia, and in selected cases, the
device was implanted in a subpectoral site.
Anticoagulation therapy with warfarin was temporarily discon-
tinued 2 day before device implantation. In some patients, who
were thought to be at high risk of thromboembolism, such as those
with a mitral mechanical valve, heparin bridging was performed.
Continuous infusion of heparin targeted the activated partial
thromboplastin time from 1.5 to 2.5 times as much as the control
value before infusion. Administration of heparin was stopped 6 h
before the procedure. Antiplatelet therapy was allowed to continue.
We did not use postoperative drainage systems because a
previous study did not ﬁnd a signiﬁcant reduction of pocket
bleedings by using drainage systems [16].
The patients were given a single dose of cefazolin (1.0 g)
intravenously just before the procedure, following a previous
study revealing the efﬁcacy of antibiotic prophylaxis before the
implantation of cardiac devices [17]. If the procedure lasted
longer than 3 h, an additional 1.0 g dose of cefazolin was added.
Infusion of heparin was restarted 3 h after the procedure and
warfarin was restarted the next day. If the patients suffered
massive bleeding during surgery, we delayed the restart of heparin
or warfarin. In addition, when the international normalized ratio
(INR) increased to 41.6, we stopped heparin infusion. The major-
ity of patients were discharged one week after the operation.4. Statistical analysis
Statistical signiﬁcance was calculated by the w2 test or Fisher’s
exact test for categorical variables and the t-test for continuous
variables. Multivariate logistic regression analysis was used to
determine signiﬁcant factors for complications. The data are
expressed as mean7standard deviation. A P valueo0.05 was
considered signiﬁcant.5. Results
Demographics and clinical characteristics of the patients are
shown in Table 1. A total of 161 consecutive patients (109 men;
mean age, 69711 years) were identiﬁed and included in the presentTable 1
Study population. Duration: February 2008–June 2009. Total implantations: 161
(men: 109, women: 52, average age, 69.0 years).
Underlying disease Device type
Af 53 (33.0%) PM 76 (47.2%)
NICM 38 (23.5%) ICD 59 (36.6%)
IHD 37 (22.9%) CRTP 11 (6.8%)
Valve 13 (8.0%) CRTD 20 (12.4%)
HD 6 (3.7%)
Medication Echocardiogram
Anticoagulation 65 (40.3%) LVDd 50.179.4 mm
Antiplatelet 55 (34.2%) LVDs 36.1712.9 mm
Dual antiplatelet 16 (9.9%) %FS 27.7%712.0%
Heparin 7 (4.3%) EF 51.9%717.0%
Af, atrial ﬁbrillation; NICM, non-ischemic cardiomyopathy; IHD, ischemic heart
disease; HD, hemodialysis; PM, pacemaker; ICD, implantable cardioverter deﬁ-
brillator CRT-P, cardiac resynchronization therapy pacemaker; CRT-D, cardiac
resynchronization therapy deﬁbrillator; LVDd, left ventricle diastolic diameter;
LVDs, left ventricle systolic diameter; FS, fractional shortening; EF, ejection
fraction.analysis. Of the 161 implanted devices included, 76 (47.2%) were
bradycardia PMs, 59 (36.6%) were ICDs, 11 (6.8%) were CRTPs, and 20
(12.4%) were CRTDs. Among the enrolled patients, 53 (33.0%) had
atrial ﬁbrillation, 38 (23.5%) had nonischemic cardiomyopathy, 37
(22.9%) had ischemic heart disease, 13 (8.0%) had valvular heart
disease, and 6 (3.7%) underwent hemodialysis. Sixty-ﬁve (40.3%)
patients took warfarin, 55 (34.2%) took single antiplatelet therapy,
and 16 (9.9%) took dual antiplatelet therapy. Heparin bridging was
performed in 7 patients. (CHADS2 score 43 in 3 patients, mitral
mechanical valve in 3 patients, left ventricle thrombus in 1 patient)
The indications for warfarin are detailed in Table 2; these include the
presence of atrial ﬁbrillation or ﬂutter in 47 (72%), low ejection
fraction (EF) in 16 (25%), and mechanical valve in 7 (10%). No patient
had deep vein thrombosis. The HAS-BLED score of all patients was
2.3571.43.6. Complications
Pocket hematoma was observed in 10 (6.2%) patients, and 4 of
10 patients received blood transfusion and 1 patient needed
evacuation for hematoma. Device infection was observed in 1
(0.6%) patient who did not experience pocket hematoma preced-
ing infection. He underwent device extraction and reimplantation
in the opposite side subpectoral site. There were no cases of
thromboembolism (Table 3). There were no differences in the
basic characteristics and underlying disease between patients
with and without complications (Table 4). CRTD implants were
more likely to be included in the complications group, but not
signiﬁcantly so. Complications were not associated with warfarin
(P¼0.19) or antiplatelet therapy (P¼0.69); however, heparin
bridging was performed signiﬁcantly more often in the complica-
tion group (P¼0.005). In heparinized patients, preoperative APTTs
were similar in the 2 groups (76.6766.6 vs. 73.379.5, P¼0.92).7. Discussion
Pocket hematoma is a frequent complication in the early
stages following cardiac device implantation and its incidence
Table 5
Multivariable analysis.
Odds ratio (95% CI) P value
Heparin 18.7 (2.2–153) 0.006
Anticoagulation 0.83 (0.16–4.25) 0.82
CRT-D 3.02 (0.56–16.4) 0.2
IHD 2.92 (0.63–13.6) 0.17
Valve 3.80 (0.45–32.0) 0.22




Complication No complication P value
(N¼10) (N¼151)
Male sex (n) 8 (80%) 101 (67%) 0.5
Age (years) 6979 69713 0.98
Height (cm) 162.578.5 170712 0.39
Weight (kg) 57.8713.9 57.0711 0.95
BMI 21.473.8 22.074.0 0.49
EF (%) 44.7719.7 52.4716.7 0.16
Af 5 (50%) 48 (32%) 0.23
IHD 4 (40%) 33 (22%) 0.18
NICM 2 (20%) 36 (24%) 0.78
Valve 2 (20%) 1 (7.3%) 0.15
HD 1 (10%) 5 (3.3%) 0.36
Anticoagulation 6 (60%) 59 (39%) 0.19
PT-INR 1.8170.59 1.4470.4 0.05
Heparin 3 (30%) 4 (2.6%) 0.005
APTT 85.6758.4 73.379.5 0.68
PT-INR 1.3970.56 1.1570.1 0.42
Antiplatelet 4 (40%) 51 (34%) 0.69
Dual antiplatelet 1 (10%) 15 (10%) 0.99
HAS-BLED 3.271.8 2.371.4 0.14
Device type
PM 2 (20%) 70 (46%) 0.19
ICD 5 (50%) 53 (35%) 0.54
CRT-P 0 (0%) 11 (7.2%)
CRT-D 3 (30%) 17 (11%) 0.08
BMI, body mass index; EF, ejection fraction; Af, atrial ﬁbrillation; IHD, ischemic
heart disease; NICM, non-ischemic cardiomyopathy; HD, hemodialysis; PM, pace-
maker; ICD, implantable cardioverter deﬁbrillator; CRT-P, cardiac resynchroniza-
tion therapy pacemaker; CRT-D, cardiac resynchronization therapy deﬁbrillator.
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patients underwent cardiac device surgery and 10 (6.2%) of these
patients had bleeding complications. The complication rate was
similar to that in previous reports. According to the multivariate
analysis, based on factors that were more frequent in the compli-
cation group (heparin, anticoagulation, CRT-D, IHD, or valve),
anticoagulation was not an independent predictor of bleeding
complications, whereas heparin bridging was the only independent
predictor of these complications (Table 5). The control of heparin
dose is thought to be appropriate because the perioperative APTTs
were no different in either group. It has been reported that heparin
use increases bleeding complications by a factor of between 2 and
10 [5,11,16,23]. In our study, bleeding complications occurred in
3 of 7 patients (43%) that had undergone heparin bridging, and the
use of heparin is an independent risk factor for perioperative
complications in the multivariable analysis, while the rate of
complication when maintaining the patient on warfarin was only
9% (6 of 65 patients). The results of our study conﬁrm previous
reports: in regard to anticoagulation, Michael et al. reported that
the use of warfarin did not increase bleeding complications [19].
Similarly, the use of warfarin was not an independent predictor in
our study.The reason why heparin bridging is recommended in device
implantation is that the effects of heparin can be reversed more
rapidly to the normal coagulation state than the effects of warfarin,
if perioperative bleeding occurs. However, this advantage may be
canceled out if the risk of bleeding in heparin bridging is higher than
with warfarin. In patients undergoing heparin bridging, the pro-
thrombin time–international normalized ratio (PT-INR) just before
surgery was slightly higher in the complication group than in the no
complication group (1.3970.56 vs. 1.1570.1). This suggests that
the effects of warfarin may remain during implantation and increase
the risk of complications. Tolosana et al. reported that there was no
difference in perioperative bleeding complications between the use
of heparin bridging and maintaining warfarin. Their protocol was to
discontinue warfarin 4 day before implantation, and PT–INR at the
time of implantation was 1.170.2 [14]. This suggests that, among
Japanese individuals, the period required for heparin bridging
should be longer because of the complete disappearance of the
warfarin effect.
In previous studies, device implantation using single or dual
antiplatelet therapy was not associated with a higher rate of
hematoma [11,12,16,18]. In our study, only one patient who was
on dual antiplatelet therapy suffered a hematoma, and this result
is similar to previous reports.
Pocket infection is another major complication of device implan-
tation. Although Klug et al. reported that hematomas are not related
to device infection, other reports have suggested that hematoma is a
risk factor [24–26]. One patient experienced device infection in this
study, but this was not related to hematoma. However, pocket
hematomas may lead to device infection at a later point following
implantation, and should therefore be monitored carefully.
The efﬁcacy of new anticoagulation agents, such as the direct
thrombin inhibitor dabigatran or factor Xa inhibitors, has been
assessed in several trials [27,28]. These data suggests that the
new agents reduce bleeding complications. The half-life of dabi-
gatran is only 12–17 h, so heparin bridging is not necessary at the
time of surgery; however, further studies are needed.8. Study limitations
Our investigation has several limitations. This study represents
a single-center experience. The sample size was relatively small
and the number of adverse events was very small. This observa-
tional study was nonrandomized, and data were analyzed retro-
spectively. Differences in technique may have occurred among
the implanting electrophysiologists and we cannot exclude the
possibility of patient selection bias. To conﬁrm these ﬁndings,
large number and multicenter prospective randomized controlled
trials are warranted.9. Conclusion
Heparin bridging may increase the risk of perioperative bleed-
ing complications in cardiac device implantation. We should
therefore reconsider anticoagulation management for individual
patients, according to the risk of thromboembolism. Further
studies are needed to evaluate the safety management of antic-
oagulation during device surgery.Conﬂict of interest
All authors have no conﬂicts of interest that should be
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